MedPage Today on MSN
Ulcerative Colitis: Next Target for CAR T-Cell Therapy?
The range of autoimmune diseases treatable with chimeric antigen receptor (CAR) T-cell therapy could be much broader than ...
A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...
For decades, diagnosis of brain cancer has been medicine’s most difficult and hazardous challenge. Simple imaging such as MRI ...
The transcription factor NF-κB is a key regulator of cell fate, extensively involved in various physiological and pathological processes such as ...
Vietnam Investment Review on MSN
Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it ...
Findings offer hope for new treatments targeting inflammation-related conditions Two new studies from the lab of Steven E.
Researchers from Mass General Brigham and the Broad Institute of MIT and Harvard have identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment ...
Scientists have engineered Salmonella bacteria to self-destruct inside tumors, releasing signals that spark powerful immune ...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback